GlassScriptPhysician profile
John J Arrotti
NPI 1790749455
$8,384.34
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,744 · 2020: $1,766 · 2021: $2,774 · 2022: $1,923 · 2023: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $177.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,414.56 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $1,114.96 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $957.63 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $555.28 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $529.76 | 2019-2023 | Eliquis |
| Pfizer INC. | $491.17 | 2019-2023 | |
| Chiesi USA, INC. | $467.22 | 2019-2023 | Cleviprex, Kengreal |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $455.00 | 2019-2023 | Lifevest |
| Amgen INC. | $449.85 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.56 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $273.41 | 2019-2022 | |
| Amarin Pharma, INC. | $252.47 | 2019-2021 | |
| Shockwave Medical, INC | $176.11 | 2022 | |
| Akcea Therapeutics, INC. | $141.59 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $139.43 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $116.45 | 2020 | |
| Novo Nordisk INC | $98.22 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $81.88 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $71.75 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $59.73 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $56.17 | 2019 | |
| Medtronic, INC. | $30.71 | 2021-2022 | |
| Astellas Pharma US INC | $24.47 | 2021 | |
| Abbott Laboratories | $23.07 | 2022 | |
| Lundbeck LLC | $22.85 | 2020 | |
| Bardy Diagnostics, INC. | $20.00 | 2019 | |
| Edwards Lifesciences Corporation | $17.33 | 2019 | |
| W. L. Gore & Associates, INC. | $15.19 | 2022 | |
| Boston Scientific Corporation | $13.99 | 2023 | |
| Angiodynamics, INC. | $13.98 | 2022 | |
| Alnylam Pharmaceuticals INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Arrotti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.